Advancing Gene, Cell, & Tissue-Based Therapies


ARM Annual Report & Sector Year in Review: 2019

The 2019 ARM Annual Report provides an overview of the organizations events, publications, and policy initiatives over the last year, with commentary from ARM members. In addition, the report contains a global sector overview detailing industry-specific statistics compiled from hundreds of cell therapy, gene therapy, tissue engineering, and other regenerative medicine therapeutic developers worldwide, including total financings, partnerships and other deals, and clinical trial information.


ARM Annual Report & Sector Year in Review: 2019

The 2019 ARM Annual Report provides an overview of the organizations events, publications, and policy initiatives over the last year, with commentary from ARM members. In addition, the report contains a global sector overview detailing industry-specific statistics compiled from hundreds of cell therapy, gene therapy, tissue engineering, and other regenerative medicine therapeutic developers worldwide, including total financings, partnerships and other deals, and clinical trial information.

European Sector Landscape

237+

Regenerative Medicine / Advanced Therapies
Companies based in Europe/Israel

United Kingdom57Switzerland16Sweden12Spain12Slovenia1Portugal3Norway3The Netherlands15Lithuania1Italy8Israel21Ireland4Greece1Germany29France31Finland2Denmark3Czech Republic2Belgium12Austria4

2019 European/Israeli Financings

Total European/ISraeli FinancingS

$3.0 Billion
Approximately €2.7 Billion

Highest Year for European Financings on Record

Gene & Gene-modified
Cell Therapy

$2.2 Billion
Approximately €2.0 Billion

2nd Highest Year on Record

Cell
Therapy

$1.7 Billion
Approximately €1.5 Billion

Highest Year on Record

Tissue
Engineering

$154 Million
Approximately €139 Million

Highest Year on Record

260

Clinical Trials
Sponsored by a European or Israeli developer as of the end of 2019

20.0%61.9%18.1%0405060708090100110120130140150160170Phase 1Phase 2Phase 3